SynBiotic SE (FRA:SBX)
Market Cap | 19.95M |
Revenue (ttm) | 3.86M |
Net Income (ttm) | -10.63M |
Shares Out | n/a |
EPS (ttm) | -2.24 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,148 |
Average Volume | 832 |
Open | 2.685 |
Previous Close | 2.640 |
Day's Range | 2.590 - 2.685 |
52-Week Range | 2.580 - 6.720 |
Beta | n/a |
RSI | 35.09 |
Earnings Date | Nov 14, 2025 |
About SynBiotic SE
SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany. [Read more]
Financial Performance
In 2023, SynBiotic SE's revenue was 3.86 million, a decrease of -52.71% compared to the previous year's 8.17 million. Losses were -10.63 million, -56.36% less than in 2022.
Financial StatementsNews

EQS-News: SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate
EQS-News: SYNBIOTIC SE / Key word(s): Statement SYNBIOTIC welcomes Green Party’s proposal for the Industrial Hemp Liberalization Act and calls for objectivity in the medical cannabis debate 21.10.2025...

Temporary headwinds from regulatory uncertainty; chg. est.
SYNBIOTIC faces short-term challenges due to regulatory uncertainties, prompting a reduction in FY25 guidance. Despite this, long-term growth potential remains, with a new BUY rating at € 6.00 PT. Jet...

EQS-News: Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals
EQS-News: SYNBIOTIC SE / Key word(s): Study/Miscellaneous Positive Outlook: Cannabis Legalization Review and Trump’s Endorsement Send Encouraging Signals 02.10.2025 / 13:26 CET/CEST The issuer is sole...

EQS-News: Across the pond: SYNBIOTIC attracts international investors with established intercontinental networks
EQS-News: SYNBIOTIC SE / Key word(s): Alliance/Strategic Company Decision Across the pond: SYNBIOTIC attracts international investors with established intercontinental networks 14.08.2025 / 11:19 CET/...

SynBiotic Eyes Triple Revenue by 2027 in Cannabis & Hemp Markets
SYNBIOTIC SE is set to triple its revenue by 2027, leveraging growth in medical cannabis and industrial hemp markets, with a strategic focus on sustainable expansion and unique investment opportunitie...

EQS-DD: SYNBIOTIC SE: HempConsult GmbH, Lending (free of charge) of 50,000 shares as part of a securities lending programme.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 23.04.2025 / 09:22 CET/CEST The issuer is solely responsi...